• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

ContraVir’s drug slashes fibrosis by 46% in preclinical study

May 31, 2018 By Sarah Faulkner

ContraVir PharmaceuticalsContraVir Pharmaceuticals (NSDQ:CTRV) touted encouraging results today from a preclinical study of its cyclophilin inhibitor, CRV431. In an animal model, the drug reduced the extent of fibrosis by 46% compared to the control.

The Edison, N.J.-based biopharma company is developing medicines to treat patients who are infected with the hepatitis B virus. In the treatment of hepatitis B, doctors often look to address the conditions that characterize liver disease – including fibrosis.

In a preclinical study, researchers gave mice streptozotocin – a chemotherapeutic – and put them on a high-fat diet. The mice were given CRV431 orally for eight weeks. ContraVir reported that the drug did not impact the animals’ body weight, liver weight or blood glucose levels. At the end of the eight-week study, researchers observed that fibrosis in the mice treated with CRV431 was reduced by 46% compared to the control group.

“The significant reduction in fibrosis development seen in this study, confirms our previous findings from a separate study conducted in Japan. Given this corroborating evidence, we see an opportunity to pursue a clinical program for CRV431 in fibrosis, expanding the potential of CRV431 beyond hepatitis B,” CEO James Sapirstein said in prepared remarks. “While we remain focused on bringing a combination cure for hepatitis B viral (HBV) infections with our TXL and CRV431 programs, we believe it is important to address the underlying hepatic tissue changes leading to the progression of liver disease, including fibrosis, cirrhosis and liver cancer.”

In an animal study of mice with hepatocellular carcinoma, ContraVir demonstrated that CRV431 lessened the number of tumor nodules by 44% and cut the overall tumor burden by 56% compared to the control group. The company noted that at the end of the 10-week study, 25% of mice treated with CRV431 had no liver tumors – meanwhile, all of the mice in the control group had at least five liver tumors.

CTRV shares were trading at $1.93 apiece today in premarket activity, up +2.7%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, Pharmaceuticals, Preclinical Trials, Wall Street Beat Tagged With: contravirpharmaceuticals

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS